Request Demo
Last update 15 Nov 2025
Infliximab biosimilar(Biocad Medical, Inc.)
Last update 15 Nov 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infliximab biosimilar, BCD-055 |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Russia (10 Jan 2018), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 69038H
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Infliximab biosimilar(Biocad Medical, Inc.)CTRI/2017/03/008063
International comparative multicenter double-blind randomized clinical study of efficacy and safety of BCD-055 (CJSC BIOCAD, Russia) and Remicade® in combination with methotrexate in patients with active rheumatoid arthritis
NCT02762812
International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in Patients With Ankylosing Spondylitis
NCT02762838
International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
100 Clinical Results associated with Infliximab biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Translational Medicine associated with Infliximab biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Patents (Medical) associated with Infliximab biosimilar(Biocad Medical, Inc.)
Login to view more data
3
Literatures (Medical) associated with Infliximab biosimilar(Biocad Medical, Inc.)01 Mar 2023Zeitschrift fur Rheumatologie
Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate
Article
Author: Lee, Young Ho ; Song, Gwan Gyu
01 Sep 2019Rheumatology internationalQ4 · MEDICINE
A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study
Q4 · MEDICINE
Article
Author: Ilivanova, Elena P ; Chernyaeva, Ekaterina V ; Nesmeyanova, Olga B ; Lila, Alexander M ; Denisov, Lev N ; Mazurov, Vadim I ; Usacheva, Julia Valentinovna ; Eremeeva, Anna V ; Ivanov, Roman A ; Dokukina, Ekaterina A
ClinicoEconomics and outcomes research : CEOR
Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
Article
Author: Hirano, Takahiro ; Laurent, Thomas ; Tsuchiya, Takanori ; Takata, Jiro ; Matsunaga, Kazuhisa ; Matsumoto, Tsugumi
100 Deals associated with Infliximab biosimilar(Biocad Medical, Inc.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Ankylosing Spondylitis | Russia | 10 Jan 2018 | |
| Rheumatoid Arthritis | Russia | 10 Jan 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 426 | cueqvtsmuv(sshczugywa) = gpdbwgyfaz ldnvlqlypd (atdprxfqal ) View more | Similar | 01 Sep 2019 | |||
cueqvtsmuv(sshczugywa) = nxpqntkgzi ldnvlqlypd (atdprxfqal ) View more | |||||||
Not Applicable | 697 | Continuer cohort | exuktknuor(auxlredeox) = azlptadywp cmckeehyiy (irwhskrapq ) | - | 05 Nov 2017 | ||
Switch cohort | exuktknuor(auxlredeox) = gisfbhzqpn cmckeehyiy (irwhskrapq ) | ||||||
Not Applicable | 768 | lgnswppern(hcavprahsa) = 34 patients stopped due to AE opxlekidyu (wkdwwsvkqn ) | Negative | 13 Nov 2016 | |||
Phase 1 | 90 | (BCD-055 Group) | govgiuauon(jfqsdwtyab) = tinuczhxix nwvxzeoazd (vcpmunhlox, jdapbwgtnf - skzpnpthsx) View more | - | 08 Jun 2016 | ||
(Remicade Group) | govgiuauon(jfqsdwtyab) = pffiwlcngl nwvxzeoazd (vcpmunhlox, zeydbedfre - ktpuvuopdg) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free